Thales Enables Teradata Vantage Customers to Protect Data at Rest With Simplicity, Speed and Scale
8.10.2020 10:00:00 EEST | Business Wire | Press release
Thales today announced a new high-performance data security solution for Teradata customers using the Vantage platform for data and analytics. By providing users with a totally transparent and scalable encryption solution to protect data at rest in any environment, the Thales Transparent Encryption solutions enable Teradata Vantage customers to better meet compliance and privacy regulations through encryption, access controls and data access audit logging.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005043/en/
(Photo: Thales)
Easily deployed across files and systems, this solution enables data at rest to be quickly encrypted within the Vantage platform. Since it is “transparent”, it is simple to deploy because there are no application development or database integration changes required. The cost-effective solution removes data breach risks and supports compliance initiatives while saving organisations months on the deployment of data protection for a Teradata environment.
Effective Access Policy Management at Scale
Thales’ Transparent Encryption is completely invisible to Vantage users and administrators as long as they are authorised to access the databases and system files they won’t know that solution is protecting your business. However, processes and actions from unauthorised users are immediately stopped and logged. The solution can be flexibly deployed across physical, virtual and cloud environments, giving organisations the ability to implement granular access policies that allow administrators to access infrastructure and systems without ever being able to see sensitive data in clear text.
The solution is designed to meet the high-scale and performance requirements of Vantage deployments on-premises, in clouds and hybrid, which can be several hundred terabytes to many petabytes in size and contain highly sensitive and regulated data and subsequently subject to privacy regulations (e.g., GDPR, CCPA, etc.). The scalable solution provides little overhead, from encryption and decryption activities, letting users robustly secure data and retain critical I/O and storage efficiencies.
“We’re pleased to have worked with the Teradata team to expand the Thales offering to include the transparent encryption solutions for Teradata. Our existing joint customers will simply expand their data security platform investment to include their Vantage environment. They will find that the policies for encryption, privileged user access and the additional security intelligence logs to further enhance their visibility are entirely familiar. New customers will be taking their first steps in unifying all their data security requirements and use cases on one easy to use, scalable and high-performance platform. The Thales solution complements the rich set of controls in the Vantage environment, ensuring that deployments meet the toughest regulatory audit scrutiny and protects a company’s most valuable data,” said Todd Moore, Senior Vice President, Encryption Solutions at Thales.
Jay Irwin JD, Director of Teradata Center for Enterprise Security added: "Teradata’s customer base is comprised of some of the largest and most data-centric companies on the planet. Security at scale is vital to this clientele, which makes Thales’ solution a particularly good fit for enabling Teradata's best-in-industry cloud security to be even more robust. With the application of Thales transparent encryption solutions, we provide a layered defense that protects customer data on-premises, in the cloud and in hybrid environments – all deployment types that our customers use today.”
About Thales
Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019.
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.
PLEASE VISIT
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005043/en/
Contact information
PRESS CONTACT
Thales, Media Relations
Constance Arnoux
+33 (0)6 44 12 16 35
constance.arnoux@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 09:00:00 EET | Press release
Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a wholly owned subsidiary of Radiology Partners, the largest radiology practice in the U.S, with more than 4,000 radiologists in its network. Cognita CXR1 applies a proprietary
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 09:00:00 EET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 09:00:00 EET | Press release
For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network operators over the air in just a few seconds, without sending a technician and with minimal disruption to merchants’ activity. For merchants, the experience is seamless: if a network becomes unstable, the payment terminal can automatically reconnect to another available network, often without the merchant even noticing. This deployment represents one of the first large-scale implementations of the SGP.32 eSIM specifi
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 09:00:00 EET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency 1 , and Core EBITDA 2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 08:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
